{"analyses":[{"ciLowerLimit":"0.663","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.167","estimateComment":"Stratified","groupDescription":"Global health status/QoL","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.357","pValueComment":"Stratified","paramType":"Hazard Ratio (HR)","paramValue":"0.879","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.24","upperLimit":"8.90","value":"6.87"},{"groupId":"OG001","lowerLimit":"3.52","upperLimit":"5.55","value":"4.60"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"263"},{"groupId":"OG001","value":"267"}],"units":"Participants"}],"description":"Time to sustained deterioration was defined as time from randomization to first worsening in QoL with no subsequent non-worsened assessment. Worsening in global health status/QoL was defined as a decrease of ≥10 points on a 100-point scale. If a participant did not report worsening, time to sustained deterioration was censored at date of last non-worsened assessment. Scores for global health status/QoL range from 0 to 100 with; higher scores representing better QoL.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ramucirumab (10 mg/kg) IV plus docetaxel (75 mg/m²) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.","id":"OG000","title":"Ramucirumab + Docetaxel"},{"description":"Placebo IV plus docetaxel (75 mg/m²) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.","id":"OG001","title":"Placebo + Docetaxel"}],"paramType":"MEDIAN","populationDescription":"All randomized participants. Censored participants: Ramucirumab + Docetaxel = 160, Placebo + Docetaxel = 173.","reportingStatus":"POSTED","timeFrame":"Randomization, 30 Days After Treatment Discontinuation (Up to 18 Months)","title":"Time to Deterioration in Quality of Life (QoL) on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) - Global Health Status/ QoL Scale","type":"SECONDARY","unitOfMeasure":"Months"}